Pritelivir is under clinical development by AiCuris Anti-infective Cures and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pritelivir’s likelihood of approval (LoA) and phase transition for Simplexvirus (HSV) Infections took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 06 Jun 2022 decreased Pritelivir’s LoA and PTSR for Genital Herpes, and decreased LoA and PTSR for Herpes Labialis (Oral Herpes).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pritelivir Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pritelivir overview

Pritelivir (AIC-316, BAY-571293) is under development for the treatment of genital herpes type 2 infection (HSV-2) and herpes labialis. The therapeutic candidate is administered orally, topically and through vaginal routes. It is a compound derived from a chemical class of thiazolylamides which acts by targeting helicase-primase.

AiCuris Anti-infective Cures overview

AiCuris Anti-infective Cures (AiCuris) is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.

Quick View Pritelivir LOA Data

Report Segments
  • Innovator
Drug Name
  • Pritelivir
Administration Pathway
  • Oral
  • Topical
  • Vaginal
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.